Jefferies’ pharma bets are Divi’s Laboratories and 3 smallcaps, with up to 30% upside. Here’s why

Jefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Sciences, and Piramal Pharma for gains up to 30%, while flagging Laurus Labs as underperforming.